Osteoarthritis

Disclaimer: This clinical reference is intended for educational purposes and to provide comprehensive medical information. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinicians must always use their independent medical judgment, consider individual patient circumstances, and consult the latest evidence and guidelines. This information may not cover all possible aspects of patient care and should not be used to make decisions about patient care without consulting a qualified healthcare professional.

Overview

• Definition: Osteoarthritis (OA) is a chronic, progressive, whole-joint disease characterized by the degeneration of articular cartilage, subchondral bone remodeling (including sclerosis and osteophyte formation), and mild synovial inflammation. This leads to joint pain, stiffness, and functional impairment. It is the most common form of arthritis.
• Epidemiology:
  • Prevalence: Highly prevalent, increasing with age. Affects an estimated 32.5 million adults in the United States.
  • Age: The strongest risk factor. Clinical OA symptoms are rare before age 40 and substantially increase after age 50. Nearly 50% of individuals over 65 years old show radiographic evidence of OA in at least one joint.
  • Sex: More common in women than men, especially for hand and knee OA, particularly after menopause. Hip OA is slightly more common in men.
  • Major Cause of Disability: A leading cause of chronic pain and disability worldwide, particularly affecting the knee, hip, and hands.
• Classification:
  • Primary (Idiopathic) OA: Most common form, without a clear, identifiable underlying cause. Often multifactorial, involving genetic, metabolic, and biomechanical factors. Can be localized (affecting one or two joints) or generalized (affecting three or more joint areas).
  • Secondary OA: Attributable to an identifiable cause that alters the joint environment, such as:
    • Post-traumatic: Due to prior joint injury (e.g., fracture, meniscal tear, ligamentous injury).
    • Developmental/Congenital: Hip dysplasia, Legg-Calve-Perthes disease.
    • Metabolic: Hemochromatosis, ochronosis, Wilson's disease, gout, pseudogout.
    • Inflammatory: Previous rheumatoid arthritis, septic arthritis.
    • Endocrine: Acromegaly, hyperparathyroidism, diabetes mellitus.
    • Other: Avascular necrosis, Paget's disease.

Pathophysiology

• Mechanism: OA is a complex interplay of mechanical stress and biological processes leading to degradation of the entire joint.
  1. Chondrocyte Dysfunction: Initial insult (mechanical or biological) leads to chondrocyte activation. Chondrocytes, instead of maintaining matrix, begin producing pro-inflammatory cytokines (e.g., IL-1β, TNF-α) and catabolic enzymes (e.g., matrix metalloproteinases [MMPs], aggrecanases [ADAMTS-4, ADAMTS-5]).
  2. Cartilage Degradation: These enzymes break down the collagen (Type II) and proteoglycans (aggrecan) within the articular cartilage matrix. This leads to cartilage softening, fibrillation, fissuring, and ultimately full-thickness loss. The repair capacity of articular cartilage is limited due to its avascular nature.
  3. Subchondral Bone Involvement: As cartilage thins, increased stress is placed on the subchondral bone. This leads to:
     • Sclerosis: Increased bone density in areas of high load.
     • Osteophyte Formation: Bony outgrowths at the joint margins, attempts by the body to stabilize the joint or increase surface area, but often lead to restricted movement and pain.
     • Subchondral Cysts: Bone marrow edema and microfractures can lead to the formation of fluid-filled cysts beneath the cartilage.
  4. Synovial Inflammation: Fragments of degraded cartilage and bone debris can irritate the synovium, leading to low-grade chronic inflammation (synovitis), which further contributes to cartilage breakdown through cytokine release.
  5. Ligament/Meniscal Damage: The entire joint is affected; ligaments can stretch, menisci can tear, contributing to instability and pain.
• Risk Factors:
  • Age: Most significant risk factor. Risk increases sharply after 50 years.
  • Obesity: Increases mechanical load on weight-bearing joints (knees, hips) and contributes metabolically through adipokine-mediated inflammation.
  • Previous Joint Injury/Trauma: Ligament tears (e.g., ACL), meniscal injuries, fractures involving a joint surface significantly increase risk.
  • Genetics: Family history, particularly for hip and hand OA. Specific gene polymorphisms are being investigated.
  • Joint Overload/Repetitive Stress: Occupations involving heavy labor, repetitive kneeling/squatting, or high-impact sports.
  • Joint Deformities: Congenital or developmental conditions (e.g., hip dysplasia, scoliosis, limb length discrepancy) alter joint mechanics.
  • Muscle Weakness: Especially quadriceps weakness for knee OA, leading to inadequate joint support.
  • Sex: Women are more affected, particularly post-menopause.
• Protective Factors:
  • Weight Management: Maintaining a healthy body mass index (BMI) significantly reduces risk, especially for knee OA.
  • Moderate Physical Activity: Regular, moderate-intensity exercise strengthens periarticular muscles, improves joint stability, and maintains cartilage health without excessive stress.
  • Injury Prevention: Avoiding high-impact trauma to joints, proper technique in sports and occupational activities.
  • Good Biomechanics: Addressing gait abnormalities, proper footwear, ergonomic adjustments.
  • Early Management of Joint Injuries: Prompt and effective treatment of acute joint injuries can mitigate long-term OA risk.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Pain: Deep, aching joint pain, usually activity-related (worse with movement/weight-bearing, relieved by rest). Progresses from intermittent to constant, eventually occurring at rest or at night.
  • Stiffness: Brief morning stiffness (typically <30 minutes, often 5-10 minutes) and "gelling" stiffness after periods of inactivity.
  • Crepitus: Grating, crackling, or popping sensation/sound during joint movement, due to roughened cartilage surfaces.
  • Reduced Range of Motion (ROM): Progressive loss of active and passive joint motion.
  • Functional Limitation: Difficulty performing activities of daily living (ADLs) such as walking, climbing stairs, dressing.
• Early Signs:
  • Intermittent pain, usually with sustained activity.
  • Mild, brief morning stiffness or stiffness after rest.
  • Occasional joint tenderness.
  • Subtle crepitus.
• Advanced Signs:
  • Constant pain, often present at rest or awakening at night.
  • Significant, persistent stiffness.
  • Gross crepitus, grinding sensation.
  • Joint swelling (due to effusions or bony enlargement).
  • Palpable osteophytes, joint line tenderness.
  • Joint instability (giving way).
  • Visible joint deformity (e.g., varus/valgus knee, Heberden's/Bouchard's nodes in hands).
  • Muscle atrophy around the affected joint.
  • Antalgic gait (limp) in lower extremity OA.
• Atypical Presentations:
  • Rapidly Progressive OA: Rare, but can occur, sometimes associated with calcium pyrophosphate deposition disease (CPPD) or specific phenotypes.
  • OA with significant inflammatory component: While low-grade inflammation is typical, prominent warmth, redness, and swelling without clear mechanical triggers might suggest an inflammatory flare, crystal arthropathy, or superimposed infection.
  • Neuropathic Pain: Some patients develop chronic pain with neuropathic features (burning, tingling), which can complicate management.

Physical Examination

• Inspection:
  • Joint Effusion: Mild to moderate swelling, particularly in the knee.
  • Bony Enlargement: Palpable and visible osteophytes (e.g., Heberden's nodes at DIPs, Bouchard's nodes at PIPs, knee osteophytes).
  • Deformity: Varus (bow-legged) or valgus (knock-kneed) angulation in knee OA, fixed flexion deformities in knee or hip OA.
  • Muscle Atrophy: Wasting of periarticular muscles (e.g., quadriceps atrophy in knee OA).
  • Gait: Antalgic gait, short stance phase on the affected side.
• Palpation:
  • Joint Line Tenderness: Localized tenderness over the joint line.
  • Crepitus: Palpable or audible grinding/crackling during active or passive range of motion.
  • Warmth: Mild warmth may be present if an effusion or inflammation is significant, but usually less pronounced than in inflammatory arthritis.
  • Periarticular Muscle Spasm: May be present due to pain.
• Special Tests:
  • Range of Motion (ROM) Assessment: Active and passive ROM will often be reduced, especially end-range motion. Compare to the contralateral side.
  • Strength Testing: Evaluate strength of muscles supporting the joint (e.g., quadriceps, gluteal muscles).
  • Stability Assessment: Assess for ligamentous laxity or instability, particularly in advanced cases.
  • Patellofemoral Grind Test (for knee OA): Pain with compression of the patella into the trochlear groove during knee flexion/extension.
  • Trendelenburg Sign (for hip OA): Pelvic drop on the unaffected side when standing on the affected leg, indicating hip abductor weakness.

Diagnostic Approach

History Taking

• Key Questions:
  • Pain Characteristics: Location, onset (insidious), quality (dull, aching), intensity, duration, aggravating (activity, weight-bearing) and alleviating factors (rest), diurnal variation (worse end of day), night pain.
  • Stiffness: Duration of morning stiffness (classic <30 mins for OA), "gelling" after inactivity.
  • Functional Impact: Difficulty with ADLs (walking, stairs, getting out of a chair, dressing, gripping objects).
  • Mechanical Symptoms: Clicking, catching, locking, buckling, giving way, crepitus.
  • Previous History: Joint injuries, surgeries, inflammatory conditions, family history of arthritis.
  • Risk Factors: Weight changes, occupation, sports participation.
  • Systemic Symptoms: Rule out inflammatory or systemic conditions (fever, weight loss, rash, polyarthralgias, profound fatigue).
• Red Flags: Warning signs requiring urgent attention:
  • Acute onset, severe pain, hot, red, swollen joint: Suggests septic arthritis (medical emergency).
  • Systemic symptoms: Unexplained fever, weight loss, night sweats (consider malignancy, infection, inflammatory arthritis).
  • Severe, rapidly progressive joint destruction: Atypical for OA; consider crystal arthropathy, neuropathic arthropathy (Charcot joint), or aggressive inflammatory arthritis.
  • New, significant neurological deficit: Especially with spinal OA, suggesting nerve root or spinal cord compression.
  • Inability to bear weight: Consider fracture, severe instability, or septic arthritis.

Laboratory Tests

• First-Line: No specific laboratory tests diagnose OA. Labs are primarily used to rule out other conditions, particularly inflammatory arthritis.
  • Complete Blood Count (CBC): Usually normal in OA. May show anemia of chronic disease in severe cases or a high WBC count in septic arthritis.
  • Erythrocyte Sedimentation Rate (ESR) and C-reactive Protein (CRP): Typically normal or only mildly elevated in OA. Significantly elevated levels suggest an inflammatory process (e.g., rheumatoid arthritis, gout, infection).
  • Rheumatoid Factor (RF) and Anti-cyclic Citrullinated Peptide (Anti-CCP) Antibodies: Negative in OA. Used to rule out rheumatoid arthritis.
  • Uric Acid: Measure if gout is suspected (though normal uric acid does not exclude gout).
  • Joint Aspiration (Arthrocentesis): If an effusion is present and septic arthritis or crystal arthropathy is suspected (acute, hot, swollen joint). Fluid analysis for cell count and differential, Gram stain, culture, and crystal analysis (polarized light microscopy).
• Confirmatory: No specific laboratory test. Diagnosis is clinical and radiographic.
• Monitoring: Primarily for medication side effects:
  • Renal function (BUN, creatinine): If on NSAIDs.
  • Liver function tests (LFTs): If on acetaminophen (high doses) or other hepatotoxic medications.
  • CBC: If on long-term NSAIDs (risk of anemia, platelet dysfunction).

Imaging

• Recommended:
  • Plain Radiographs (X-rays): First-line imaging for diagnosis and staging.
    • Weight-bearing views are crucial for lower extremity joints (knees, hips) as joint space narrowing is often only apparent under load. AP, lateral, and Merchant (patellofemoral) views for the knee; AP and lateral for the hip.
    • Characteristic findings:
      • Joint Space Narrowing (JSN): Asymmetric loss of cartilage, particularly in weight-bearing areas.
      • Osteophytes: Bony spurs at the joint margins.
      • Subchondral Sclerosis: Increased bone density beneath the cartilage.
      • Subchondral Cysts: Radiolucent areas beneath the joint surface.
    • Kellgren-Lawrence (K-L) Grading System: A common radiographic classification:
      • Grade 0: No radiographic features of OA.
      • Grade 1: Doubtful JSN, possible osteophytic lipping.
      • Grade 2: Definite osteophyte, possible JSN on weight-bearing films.
      • Grade 3: Moderate multiple osteophytes, definite JSN, some sclerosis, possible bony deformity.
      • Grade 4: Large osteophytes, marked JSN, severe sclerosis, definite bony deformity.
• Advanced:
  • Magnetic Resonance Imaging (MRI): Not routinely needed for OA diagnosis. Useful when:
    • Symptoms are out of proportion to X-ray findings.
    • Considering surgery and need to assess soft tissues (menisci, ligaments, articular cartilage defects more precisely than X-ray).
    • Suspecting other pathologies (e.g., osteonecrosis, stress fracture, specific meniscal or ligamentous injury, bone marrow edema).
  • Computed Tomography (CT): Rarely used for primary diagnosis of OA. Can be helpful for:
    • Detailed assessment of complex bony deformities, especially for surgical planning (e.g., osteotomy or total joint replacement).
    • Evaluating spinal stenosis or osteophyte impingement in spinal OA.
  • Ultrasound: Can visualize joint effusions, synovitis, osteophytes, and guide injections, but not primary for OA diagnosis.

Management

Management of OA is a multi-modal approach, emphasizing non-pharmacological therapies first, followed by pharmacological interventions, and ultimately surgery for refractory cases.

Acute Management

Refers to managing acute flares or exacerbations of chronic OA pain. - Immediate: * Rest: Temporary avoidance of aggravating activities. * Ice/Heat: Local application for pain relief and reducing swelling. Ice for acute pain/swelling, heat for chronic stiffness. * Topical Analgesics: Over-the-counter options like capsaicin cream or topical NSAIDs (e.g., diclofenac gel 1%). - Stabilization: * Oral Analgesics: Short course of non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen 200-400 mg every 4-6 hours PRN, naproxen 220-500 mg BID) if no contraindications. Consider COX-2 selective NSAIDs (celecoxib 100-200 mg BID) for patients at higher GI risk. * Intra-articular Corticosteroid Injection: Can provide rapid, short-term pain relief (weeks to months) for acute flares, especially with effusion. Dosing: Triamcinolone 20-40 mg or Methylprednisolone 40-80 mg (for large joints like knee), with lidocaine. Limit to 3-4 injections per year per joint due to potential for cartilage damage. - Emergency: * Septic Arthritis: If acute, hot, red, severely painful joint with systemic symptoms, immediate joint aspiration for diagnosis, IV antibiotics, and potentially surgical lavage are required. * Fracture: If trauma or severe, new onset pain with inability to bear weight, investigate for fracture.

Chronic Management

The cornerstone of OA management, aiming to reduce pain, improve function, and slow disease progression.

Non-pharmacological

These are first-line therapies for all patients with OA. - Patient Education and Self-Management: Crucial for understanding the disease, setting realistic expectations, and empowering patients to manage their condition. - Exercise: Core treatment. * Aerobic Exercise: Low-impact activities (walking, swimming, cycling) 30 minutes, 3-5 times/week to improve cardiovascular health, reduce weight, and boost mood. * Strengthening Exercises: For periarticular muscles (e.g., quadriceps for knee OA, hip abductors for hip OA) to improve joint stability and reduce load. * Range of Motion Exercises: To maintain joint flexibility. * Neuromuscular/Balance Training: Improves proprioception and reduces fall risk. * Physical Therapy (PT) and Occupational Therapy (OT): Essential for individualized exercise programs, gait training, assistive device prescription, and joint protection strategies. - Weight Loss: Highly recommended for overweight/obese patients with knee or hip OA. Even modest weight loss (e.g., 5-10% of body weight) can significantly reduce pain and improve function by decreasing mechanical load and reducing systemic inflammatory mediators. - Assistive Devices: Canes, walkers (used on the contralateral side to the affected joint) to offload weight and improve stability. - Bracing: Unloader braces for knee OA (varus or valgus deformity) to redistribute load. Patellar bracing for patellofemoral OA. - Footwear/Orthotics: Shock-absorbing shoes, lateral-wedge insoles for medial compartment knee OA, custom orthotics to correct biomechanical alignment. - Thermotherapy: Heat (warm compresses, warm baths) for stiffness, cold packs for pain and swelling. - Acupuncture: May provide modest short-term pain relief, but evidence is mixed, often considered as an adjunct therapy. - Transcutaneous Electrical Nerve Stimulation (TENS): Can provide temporary pain relief for some patients.

Pharmacological

Medication choices depend on pain severity, patient comorbidities, and risk factors. - Topical Agents: * Topical NSAIDs (e.g., Diclofenac 1% gel, 2-4 g applied 3-4 times daily): Recommended for knee and hand OA, especially for mild-moderate pain or in patients with contraindications to oral NSAIDs. Lower systemic absorption, fewer GI/CV side effects than oral NSAIDs. * Capsaicin Cream (0.025-0.075%): Apply 3-4 times daily. Requires consistent use for weeks; causes initial burning sensation. - Oral Analgesics: * Acetaminophen (Paracetamol): Up to 1000 mg 3-4 times daily (max 4 g/day). Formerly first-line, but recent evidence suggests limited efficacy, especially in knee/hip OA. Still considered for mild pain or those who cannot take NSAIDs. Caution with liver disease. * Oral NSAIDs (Non-Selective: Ibuprofen, Naproxen; COX-2 Selective: Celecoxib): More effective than acetaminophen for moderate-severe OA pain. * Non-selective: * Ibuprofen: 400-800 mg TID-QID (max 2400-3200 mg/day). * Naproxen: 250-500 mg BID (max 1000 mg/day). * COX-2 selective (Celecoxib): 100-200 mg BID (max 400 mg/day). Lower GI risk but similar cardiovascular risk to non-selective NSAIDs. * Considerations: Use lowest effective dose for shortest duration. Monitor for GI (ulcer, bleed), renal (AKI, fluid retention), and cardiovascular (hypertension, MI, stroke) side effects. Co-prescribe proton pump inhibitors (PPIs) for patients at high GI risk (history of ulcer, elderly, concomitant corticosteroids/anticoagulants). * Duloxetine (Cymbalta): Serotonin-norepinephrine reuptake inhibitor (SNRI), effective for chronic musculoskeletal pain, including OA, especially if neuropathic pain or depression is present. Dosing: 30 mg daily for 1 week, then 60 mg daily (max 120 mg/day). * Tramadol: Weak opioid, often combined with acetaminophen. Dosing: 50-100 mg every 4-6 hours PRN (max 400 mg/day). Considered for moderate-severe pain when other options fail or are contraindicated. Caution: Risk of dependence, serotonin syndrome (with other serotonergic drugs), seizures. * Opioids (stronger): Generally not recommended for chronic OA pain due to risks of dependence, abuse, hyperalgesia, and side effects. Reserve for severe, refractory pain in carefully selected patients, with careful monitoring and limited duration. - Intra-articular Injections: * Corticosteroids: Dexamethasone, triamcinolone, methylprednisolone. Provide short-term pain relief (weeks to a few months) by reducing inflammation. Useful for acute flares. Limit frequency to 3-4 injections per year per joint to avoid potential cartilage damage. * Hyaluronic Acid (Viscosupplementation): A series of injections (1-5, weekly) aimed at restoring synovial fluid viscoelasticity. Evidence for efficacy is modest and controversial; some guidelines recommend against routine use, while others suggest it for specific patients who fail other therapies. Effect onset is slower but potentially longer lasting than corticosteroids. * Platelet-Rich Plasma (PRP): Autologous blood product thought to promote healing. Emerging evidence for OA but not yet standard of care; variable preparation methods, inconsistent results. - Other Oral Agents (Limited/No Recommendation): * Glucosamine and Chondroitin Sulfate: Widely used, but meta-analyses show inconsistent and largely non-significant effects on pain or joint structure. Most major guidelines do not recommend their routine use.

Surgical Management

Considered when conservative measures have failed, pain is severe, and functional impairment significantly impacts quality of life. - Arthroscopy: Primarily diagnostic or for managing specific mechanical symptoms (e.g., loose bodies, meniscal tears). Not recommended for routine debridement or lavage in knee OA as it does not improve outcomes more than physical therapy. - Osteotomy: Realignment surgery (e.g., high tibial osteotomy for medial compartment knee OA) to shift weight-bearing to a healthier part of the joint. More often for younger, active patients with unicompartmental OA. - Arthroplasty (Joint Replacement Surgery): Definitive treatment for end-stage OA. * Total Joint Arthroplasty (TJA): Total knee replacement (TKR) or total hip replacement (THR). Highly effective for severe pain relief and functional improvement. * Partial Joint Arthroplasty: Unicompartmental knee replacement. - Arthrodesis (Joint Fusion): Rarely used, primarily for severe pain in smaller joints (e.g., ankle, hand, spine) when motion preservation is not critical, or TJA is contraindicated/failed.

Monitoring

• Clinical Assessment: Regular evaluation of pain, function (e.g., WOMAC score), quality of life, and treatment effectiveness.
• Medication Side Effects: Routine monitoring for adverse effects of pharmacological agents (e.g., GI, renal, CV for NSAIDs; liver for acetaminophen).
• Disease Progression: Radiographic monitoring is typically not needed frequently, but can be done if there is a rapid change in symptoms or consideration for surgical intervention.

Treatment Algorithms

Treatment should be individualized based on pain severity, functional impairment, specific joint involved, patient comorbidities, and preferences.

• First-Line (Initial/Mild-Moderate OA):
  1. Patient Education: Explaining the disease, self-management strategies.
  2. Non-Pharmacological:
     • Exercise: Tailored program (strengthening, aerobic, flexibility).
     • Weight Loss: For overweight/obese patients.
     • Physical Therapy/Occupational Therapy: For gait training, assistive device use, joint protection.
     • Heat/cold application.
  3. Topical NSAIDs: Especially for knee and hand OA.
  4. Acetaminophen: For mild pain (consider limited efficacy).
• Second-Line (Moderate-Severe OA or failure of First-Line):
  1. Oral NSAIDs: Consider non-selective or COX-2 selective, with caution, lowest effective dose, shortest duration, and GI/CV protection as appropriate.
  2. Duloxetine: Especially if neuropathic pain component or depression.
  3. Intra-articular Corticosteroid Injections: For acute flares and short-term relief.
  4. Tramadol: For moderate-severe pain refractory to NSAIDs, with careful risk assessment.
  5. Assistive Devices/Bracing: If not already implemented.
• Refractory Cases (Severe OA, persistent pain, significant functional limitation despite comprehensive conservative management):
  1. Referral to Orthopedic Surgeon: For evaluation of surgical options (arthroplasty, osteotomy). This is generally considered when pain is debilitating, significantly impacting quality of life, and all reasonable conservative measures have failed.

Complications

• Common:
  • Chronic Pain: Persistent pain, often leading to reduced physical activity.
  • Functional Limitation: Difficulty with ADLs, reduced mobility, decreased independence.
  • Joint Stiffness: Especially after rest.
  • Muscle Weakness and Atrophy: Due to disuse and pain inhibition.
  • Joint Deformity: Visible changes in joint alignment (e.g., varus/valgus in knees, Heberden's/Bouchard's nodes).
  • Joint Instability: Sensation of "giving way."
  • Sleep Disturbance: Due to pain at night.
  • Psychological Distress: Increased risk of depression and anxiety due to chronic pain and functional loss.
  • Falls: Increased risk in older adults due to pain, weakness, and instability.
  • Medication Side Effects: From long-term use of NSAIDs (GI bleeding, renal impairment, cardiovascular events) or opioids (dependence, constipation, sedation).
• Serious:
  • Severe Disability: Leading to complete loss of joint function, requiring joint replacement.
  • Pathologic Fracture: Rare, but severe subchondral bone changes or cysts can weaken bone.
  • Septic Arthritis: Although rare, a previously damaged joint or one that has received injections is at slightly higher risk.
  • Acute Compartment Syndrome: Extremely rare, but can occur after joint replacement surgery.
• Long-term:
  • Need for Joint Replacement Surgery: For end-stage disease.
  • Chronic Pain Syndrome: Development of centralized pain, persistent despite treatment.
  • Reduced Quality of Life: Impact on social activities, work, and overall well-being.
  • Increased Morbidity: Due to inactivity leading to cardiovascular disease, diabetes, and other comorbidities.

Prognosis

• Factors Affecting Outcome:
  • Severity at Presentation: More severe radiographic OA and higher pain levels at baseline predict worse outcomes.
  • Joint Involved: Hip and knee OA tend to be more disabling than hand OA.
  • Obesity: Associated with faster progression and poorer outcomes, particularly in the knee.
  • Age: Older age is associated with more severe disease and potentially slower recovery from surgery.
  • Comorbidities: Presence of other chronic conditions (e.g., cardiovascular disease, diabetes, depression) can complicate management and worsen outcomes.
  • Adherence to Treatment: Patients who consistently engage in non-pharmacological therapies and adhere to medication regimens generally have better outcomes.
  • Muscle Strength: Strong periarticular muscles are protective and improve function.
  • Psychological Factors: Depression and anxiety can exacerbate pain perception and functional limitations.
• Survival: OA itself is not a direct cause of mortality. However, severe OA can lead to reduced physical activity, contributing to an increased risk of cardiovascular disease, diabetes, and obesity-related complications, which can indirectly impact life expectancy. Joint replacement surgery generally has low mortality rates.
• Quality of Life: Significantly reduced in patients with moderate to severe OA due to pain, stiffness, and functional limitations. Effective management, particularly joint replacement surgery for end-stage disease, can dramatically improve quality of life, reduce pain, and restore function. Prognosis for pain relief and functional improvement post-TJA is generally excellent.

Prevention

• Primary Prevention (Preventing Initial Occurrence):
  • Weight Management: Maintain a healthy BMI (18.5-24.9 kg/m²) throughout life.
  • Regular, Moderate Exercise: Engage in low-impact physical activity to strengthen muscles and maintain joint health without excessive stress. Avoid high-impact or repetitive joint loading activities that could lead to injury.
  • Injury Prevention: Use proper techniques in sports and work. Wear appropriate protective gear. Address joint instability promptly.
  • Ergonomic Modifications: Adjust workplace and home environments to minimize joint stress.
  • Address Joint Deformities: Correctable congenital or developmental joint abnormalities (e.g., hip dysplasia) early in life.
• Secondary Prevention (Early Detection and Intervention):
  • Early Diagnosis: Prompt recognition of early OA symptoms.
  • Aggressive Non-Pharmacological Management: Implement exercise, weight loss, and physical therapy early to slow progression and manage symptoms.
  • Risk Factor Modification: Control modifiable risk factors (e.g., obesity, occupational stresses).
  • Management of Acute Joint Injuries: Prompt and thorough rehabilitation after ligamentous tears, meniscal injuries, or fractures to minimize long-term OA risk.
• Tertiary Prevention (Preventing Complications and Improving Function in Established OA):
  • Comprehensive Pain Management: Using multi-modal strategies to control chronic pain.
  • Functional Rehabilitation: Continued physical and occupational therapy to maintain or improve joint function and mobility.
  • Fall Prevention Programs: For older adults with OA, including exercise to improve balance and strength.
  • Medication Monitoring: Vigilant monitoring for and management of medication side effects.
  • Psychological Support: Addressing depression and anxiety to improve coping and adherence to treatment.
  • Timely Surgical Intervention: When conservative measures fail, to restore function and alleviate pain before irreversible damage or severe deconditioning occurs.

Special Populations

• Pediatric:
  • Rarely seen as primary OA. When present, it is almost always secondary to underlying conditions such as developmental hip dysplasia, Legg-Calve-Perthes disease, slipped capital femoral epiphysis, juvenile idiopathic arthritis, or post-traumatic.
  • Management focuses on treating the underlying cause, preserving joint function, and delaying progression. Surgical correction of deformities is more common.
• Geriatric:
  • Increased prevalence and severity due to age-related changes and cumulative joint stress.
  • Polypharmacy: High risk of drug-drug interactions, particularly with NSAIDs in patients on anticoagulants, antihypertensives, or diuretics.
  • Comorbidities: Higher rates of cardiovascular disease, renal impairment, and diabetes; these necessitate cautious use of NSAIDs and careful monitoring.
  • Cognitive Impairment: May affect adherence to exercise programs and medication regimens.
  • Focus: Emphasis on non-pharmacological treatments. When using medications, "start low, go slow." Topical agents preferred over oral for localized pain. Careful assessment of fall risk.
• Pregnancy:
  • Pharmacological options are limited due to potential fetal harm.
  • Acetaminophen: Generally considered safe throughout pregnancy for pain.
  • NSAIDs: Avoid, especially in the third trimester due to risk of premature closure of the ductus arteriosus and fetal renal dysfunction.
  • Opioids: Use with extreme caution and only if absolutely necessary due to risk of neonatal withdrawal syndrome.
  • Non-pharmacological: Physical therapy, heat/cold, exercise, and assistive devices are the mainstays of treatment.
  • Weight gain during pregnancy can exacerbate weight-bearing joint pain.
• Comorbidities:
  • Cardiovascular Disease (CVD) and Hypertension: NSAIDs (both non-selective and COX-2 selective) increase the risk of cardiovascular events (MI, stroke) and can elevate blood pressure. Use with extreme caution, consider topical NSAIDs or duloxetine.
  • Renal Impairment: NSAIDs can worsen renal function. Avoid or use with extreme caution and frequent monitoring of renal function (BUN, creatinine).
  • Gastrointestinal (GI) Disease (e.g., peptic ulcer disease): NSAIDs increase risk of GI bleeding. If NSAIDs are necessary, co-prescribe a PPI (e.g., omeprazole 20 mg daily) or use a COX-2 selective NSAID (celecoxib). Topical NSAIDs are safer.
  • Diabetes Mellitus: Intra-articular corticosteroids can transiently elevate blood glucose levels; monitor closely. Weight loss is particularly important for these patients.

Clinical Pearls

• Diagnostic:
  • OA is primarily a clinical diagnosis: Based on history (activity-related pain, brief morning stiffness) and physical exam (crepitus, reduced ROM, bony enlargement). X-rays confirm and stage the disease, but symptoms do not always correlate with radiographic severity.
  • "Treat the patient, not the X-ray": Patients with severe radiographic OA may have mild symptoms, and vice versa. Focus on functional impairment and pain levels.
  • Rule out red flags: Always consider and exclude inflammatory arthritis, septic arthritis, or other urgent conditions, especially with atypical presentations (acute onset, severe systemic symptoms, prominent warmth/redness).
  • Weight-bearing X-rays are crucial for lower extremity OA: They best demonstrate joint space narrowing.
• Treatment:
  • Non-pharmacological therapies are foundational: Education, exercise, and weight loss are the most important first-line interventions for all patients.
  • Start low, go slow with pharmacotherapy: Begin with topical agents or acetaminophen, then carefully consider oral NSAIDs, tramadol, or injections, always weighing benefits against risks.
  • NSAIDs are effective but come with risks: Always assess GI, CV, and renal risk factors before prescribing, and consider protective measures (PPIs, lowest dose, shortest duration).
  • Avoid chronic opioid use: Strong opioids have limited long-term efficacy and significant risks for chronic non-cancer pain.
  • Injections are for temporary relief: Corticosteroid injections provide short-term relief for flares; hyaluronic acid's benefit is modest and controversial.
  • Surgery is for end-stage disease: Reserve joint replacement for patients with severe pain and functional limitation refractory to all conservative measures.
• Pitfalls:
  • Over-reliance on imaging: Ordering unnecessary MRIs for typical OA, or solely treating X-ray findings without correlating with patient symptoms.
  • Under-utilizing non-pharmacological therapies: Neglecting exercise, weight loss, and physical therapy in favor of medications.
  • Prolonged, indiscriminate use of oral NSAIDs: Leading to preventable GI, renal, or cardiovascular complications.
  • Ignoring comorbidities: Failing to adjust medication choices based on patient's other health conditions (e.g., giving NSAIDs to a patient with heart failure or renal insufficiency).
  • Not addressing psychological factors: Overlooking depression or anxiety, which can significantly amplify pain and disability.

Recent Updates

• Guidelines:
  • American College of Rheumatology (ACR) 2019 Guideline: Emphasizes exercise, weight loss, and self-management education as core treatments. Recommends topical NSAIDs over oral NSAIDs for knee/hand OA. Downgrades strong recommendation for acetaminophen, glucosamine, chondroitin, and most opioids for knee/hip OA.
  • Osteoarthritis Research Society International (OARSI) 2019 Guidelines: Similarly emphasize non-pharmacological approaches. Provide specific recommendations for different OA phenotypes and joints. Highlights strong evidence for exercise, weight management, and self-efficacy programs.
  • National Institute for Health and Care Excellence (NICE) 2020 Guidelines (UK): Strong focus on non-pharmacological interventions, exercise, and weight management. Discourages glucosamine, chondroitin, and routine arthroscopy.
• Evidence:
  • Role of Inflammation: Growing recognition of low-grade synovial inflammation as a key driver in OA pathogenesis, leading to research into anti-inflammatory targets beyond traditional NSAIDs.
  • Phenotyping OA: Research is moving towards identifying distinct OA phenotypes (e.g., metabolic, inflammatory, post-traumatic, mechanical) to allow for more personalized treatment approaches.
  • Novel Drug Targets: Ongoing research into nerve growth factor (NGF) inhibitors (e.g., tanezumab) showing promise for pain relief, but with concerns regarding rapidly progressive OA (RPOA) and safety, limiting widespread use currently. Other targets include anti-NGF, anti-IL-1, anti-TNF, and disease-modifying OA drugs (DMOADs) which are still largely in experimental stages.
  • Autologous Biologics: Continued research into PRP and stem cell therapies, with varying results and lack of definitive, large-scale, high-quality evidence to support routine use.
• Controversies:
  • Efficacy of Hyaluronic Acid (Viscosupplementation): Remains debated among various guidelines and systematic reviews, with some finding only modest or no benefit compared to placebo.
  • Role of Arthroscopy for Degenerative Meniscal Tears in OA: Strong evidence suggests that arthroscopic partial meniscectomy in patients with knee OA and degenerative meniscal tears is no better than sham surgery or physical therapy for pain and function. It is generally not recommended.
  • Long-term Safety and Efficacy of Opioids for Chronic Non-Cancer Pain: Continues to be a major public health concern, with increasing consensus against their routine use in OA due to risks of dependence and limited long-term benefit.

Key References

• Guidelines:
  • Kolasinski SL, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020 Feb;72(2):220-233.
  • Bannuru RR, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Nov;27(11):1578-1589.
  • National Institute for Health and Care Excellence (NICE). Osteoarthritis: care and management. NICE guideline [NG215]. Published: 2020 Oct 14.
• Studies:
  • McAlindon TE, et al. Effect of Glucosamine and Chondroitin Sulfate on Pain in Knee Osteoarthritis: A Randomized Controlled Trial. JAMA. 2016 Feb 23;315(9):894-903.
  • Jansen J, et al. The effect of oral paracetamol on pain in knee and hip osteoarthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2020 Feb;50(1):154-161.
  • Katz JN, et al. Surgery versus Physical Therapy for a Meniscal Tear and Osteoarthritis. N Engl J Med. 2013 Dec 26;369(26):2515-2524.
• Reviews:
  • Glyn-Jones S, et al. Osteoarthritis. Lancet. 2015 Jul 25;386(9991):376-87.
  • Hunter DJ, et al. Osteoarthritis. Part 1: Pathogenesis. Ann N Y Acad Sci. 2018 Oct;1426(1):5-13.

---

Disclaimer: This clinical reference is intended for educational purposes and to provide comprehensive medical information. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinicians must always use their independent medical judgment, consider individual patient circumstances, and consult the latest evidence and guidelines. This information may not cover all possible aspects of patient care and should not be used to make decisions about patient care without consulting a qualified healthcare professional.